Neuropathological characteristics among the CTE and AD groups
| CTE | AD | P value | |||||
| Total # | n | % | Total # | n | % | ||
| AD neuropathological change | 6 | 25 | <0.001* | ||||
| Low | 0 | 0 | 0 | 0 | |||
| Intermediate | 3 | 50 | 0 | 0 | |||
| High | 3 | 50 | 25 | 100 | |||
| Cerebral amyloid angiopathy | 6 | 5 | 80 | 24 | 21 | 88 | 0.41 |
| α-S Lewy bodies | 6 | 1 | 25 | 13 | 0.53 | ||
| Brainstem predominant | 0 | 0 | 1 | 4 | |||
| Limbic | 0 | 0 | 3 | 12 | |||
| Neocortical (diffuse) | 1 | 16.7 | 2 | 8 | |||
| Amygdala predominant | 0 | 0 | 6 | 24 | |||
| Olfactory bulb | 0 | 0 | 1 | 4 | |||
| MSA synucleinopathy | 6 | 0 | 0 | 25 | 0 | 0 | |
| FTLD-tau | |||||||
| Pick’s disease | 6 | 1 | 16.7 | 25 | 0 | 0 | 0.04* |
| Corticobasal degeneration | 6 | 0 | 0 | 25 | 0 | 0 | |
| Progressive supranuclear palsy | 6 | 1 | 16.7 | 25 | 3 | 12 | 0.76 |
| Argyrophilic grain disease | 6 | 1 | 16.7 | 25 | 14 | 56 | 0.08 |
| FTLD-TDP-43 | 6 | 2 | 33.3 | 18 | 1 | 5.6 | 0.08 |
| Amygdala | 5 | 4 | 80 | 16 | 5 | 31.3 | 0.06 |
| Hippocampus | 4 | 3 | 75 | 12 | 5 | 41.7 | 0.25 |
| Entorhinal temporal cortex | 6 | 5 | 83.3 | 17 | 4 | 23.5 | 0.01* |
| Neocortical | 3 | 3 | 100 | 11 | 2 | 18.2 | 0.009* |
| Prion disease | 6 | 0 | 0 | 25 | 0 | 0 | |
| Hippocampal sclerosis | 6 | 3 | 50 | 24 | 1 | 4.2 | 0.01* |
| Neoplasm | 6 | 0 | 0 | 25 | 0 | 0 | |
| Contusion-TBI | 6 | 1 | 16.7 | 25 | 0 | 0 | 0.04* |
| Arteriosclerosis | 6 | 17 | 0.26 | ||||
| Mild | 2 | 33.3 | 12 | 70.6 | |||
| Moderate | 2 | 33.3 | 3 | 17.6 | |||
| Severe | 2 | 33.3 | 2 | 11.8 | |||
*Difference between the groups statistically significant (p < .05).
AD, Alzheimer’s disease; CTE, chronic traumatic encephalopathy; FTLD, frontal temporal lobar degeneration; MSA, multiple system atrophy; α-S, alpha-synuclein; TBI, traumatic brain injury; TDP-43, TAR DNA binding protein 43; Total #, the total number of cases examined for pathology.